Invitae Corp NVTA
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover NVTA, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Invitae Reports Third Quarter 2023 Financial Results
-
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
-
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
-
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
-
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
-
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
-
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics
-
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
Trading Information
- Previous Close Price
- $0.54
- Day Range
- $0.48–0.53
- 52-Week Range
- $0.38–3.10
- Bid/Ask
- $0.50 / $0.51
- Market Cap
- $144.82 Mil
- Volume/Avg
- 5.1 Mil / 10.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.29
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,700
- Website
- https://www.invitae.com
Valuation
|
Metric
|
NVTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NVTA
|
|---|---|
Quick Ratio | 2.13 |
Current Ratio | 2.39 |
Interest Coverage | −37.30 |
Quick Ratio
NVTA
Profitability
|
Metric
|
NVTA
|
|---|---|
Return on Assets (Normalized) | −18.15% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −16.99% |
Return on Assets
NVTA
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Wcw | $189.4 Bil | |
DHR
| Danaher Corp | Tdllrq | $162.6 Bil | |
IDXX
| IDEXX Laboratories Inc | Dcgwh | $39.8 Bil | |
IQV
| IQVIA Holdings Inc | Hmlkmp | $38.5 Bil | |
A
| Agilent Technologies Inc | Gfvf | $36.6 Bil | |
MTD
| Mettler-Toledo International Inc | Yhltxh | $23.4 Bil | |
ICLR
| Icon PLC | Gnbzck | $22.2 Bil | |
LH
| Laboratory Corp of America Holdings | Cttcvk | $18.1 Bil | |
WAT
| Waters Corp | Gcz | $16.4 Bil | |
DGX
| Quest Diagnostics Inc | Prffc | $15.2 Bil |